Botulinum toxin A injection - Revance Therapeutics

Drug Profile

Botulinum toxin A injection - Revance Therapeutics

Alternative Names: DaxibotulinumtoxinA Injection; RT-002

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Revance Therapeutics
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Torticollis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glabellar lines
  • Phase II Plantar fasciitis; Torticollis
  • No development reported Skin disorders

Most Recent Events

  • 08 Jan 2018 Interim safety and efficacy data from a phase IIa trial in Plantar fasciitis released by Revance Therapeutics
  • 08 Jan 2018 Revance Therapeutics plans a phase IIa trial for Plantar fasciitis (Trial profile 700292115)
  • 04 Jan 2018 Revance Therapeutics plans a phase IIb trial for plantar fasciitis, in the second half of 2018 (Trial profile 700292058)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top